Dr. Bruce S. Spinowitz, MD

Dr. Spinowitz practices at Nephrology Associates in Bronx, New York.

Dr. Spinowitz's NPI, 1467475962, was assigned on July 25, 2006. Dr. Spinowitz graduated from New York University Grossman School of Medicine in 1973. Dr. Spinowitz holds New York license 120445.

Dr. Spinowitz's primary practice is Nephrology Associates, at 1874 Pelham S Pkwy, Bronx, NY 10461 in Bronx County. The practice phone is (718) 931-5800.

Dr. Spinowitz's primary practice is Nephrology Associates in Bronx, New York. Dr. Spinowitz is also affiliated with NewYork-Presbyterian Queens. The medical group on file is Nephrology Associates. Dmand AI also links Dr. Spinowitz to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Spinowitz practices, 3 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Spinowitz's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Spinowitz is licensed in New York.

CMS data shows 1,180 Medicare services from Dr. Spinowitz across 9 procedure codes in 2024, for 213 Medicare patients. Medicare paid $75,923 for them.

CMS counts 213 Medicare patients who saw Dr. Spinowitz in 2024. The largest group is 75 to 84, with 77 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 34% are also on Medicaid. Their average risk score is 3.81, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Spinowitz's median patient age at 74, with 33% women.

In 2024, Dr. Spinowitz wrote 290 Medicare Part D claims for 55 patients. 78% of them were for generic drugs. CMS names the drug for 174 of them, across 8 drugs with 11 or more claims each, at $68,624 in total drug cost. In 2023, CMS named 143 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Spinowitz for performance year 2024, reported through an alternative payment model (APM). Dr. Spinowitz accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 27 papers to Dr. Spinowitz, published from 2007 to 2024. 2019 was the busiest year, with 4. The most frequent topics are Renal Insufficiency, Chronic, Hyperkalemia and Potassium. Dr. Spinowitz has published most often in Nephrol Dial Transplant. Dr. Spinowitz's most frequent co-authors are Pablo Ezequiel Pergola, MD, Peter Andrew McCullough, MD, MPH and Glenn Matthew Chertow, MD.

Dmand AI links Dr. Spinowitz to 3 clinical trials, 2 of them phase 3 studies. Conditions studied include Nephritis, Hereditary, Polycystic Kidney, Autosomal Dominant and Collagen Diseases. Biogen sponsors the most, 3.

CMS Open Payments shows 628 general payments to Dr. Spinowitz from 29 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 46% of the total. AstraZeneca Pharmaceuticals LP paid the most, $357,660.

Dr. Spinowitz graduated from New York University Grossman School of Medicine in 1973.